This news release contains forward-looking statements that are based on
the Company’s current beliefs and assumptions
and on information currently available to its management.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the Company’s
actual results, performance or achievements to be materially different
from any future results, performance Read the rest of this entry »

Cosmetic drugmaker Allergan Inc. said Friday its eyelash treatment Latisse received Food and Drug Administration approval.
The drug treats the condition hypotrichosis of the eyelashes and is applied once-daily to increase thickness and fullness, the company said. The treatment has full results within 16 weeks, it said.
“Latisse fulfills a significant and previously unmet need in the medical aesthetic marketplace with a product approved by the Read the rest of this entry »

– Cancer was once assumed to be a death sentence because the disease was often incurable, but a new survey suggests the crisis for many today is paying for available treatments.
“It is a big surprise that 20 percent of people with health insurance can’t afford to have the cancer therapy they need to save their lives,” said John Seffrin of the American Cancer Society.
The survey, jointly conducted by ACS and the
, includes 20 profiles of cancer Read the rest of this entry »

GEA, a relatively new procedure, has been regarded as being just as effective as hysterectomies while being less invasive with slightly lower complication rates and costs. During the surgery, heat, cold, microwave or radiofrequency energy is used to destroy only the uterine lining while keeping the uterus intact. Scar tissue then forms and monthly menstrual flow and its pain typically decrease.
The Mayo Clinic study, published in the January issue Read the rest of this entry »

From Wikinews, the free news source you can write!
Tuesday, November 4, 2008
The most common type of brain tumor,
, may be getting a new
-approved treatment soon. Yesterday the pharmaceutical firm
announced that it is requesting accelerated approval for its drug Avastin as a glioblastoma treatment. Avastin is already approved for use on lung, colon and breast cancers. Promising results in Phase II clinical trials led the company to seek Read the rest of this entry »

The enactment of a federal mental health and substance abuse parity law by Congress this month will broadly outlaw insurance discrimination against people with mental illness and substance-use disorders. Indiana’s congressional delegation should be applauded for its support of this important legislation, which will benefit more than 113 million Americans.
This law recognizes that mental health and substance-use conditions are real and treatable Read the rest of this entry »

MONTEREY, CA, USA (UroToday.com) – Margaret Pearle presented a State-of-the-Art lecture on the metabolic aspects of urolithiasis at the 84th annual meeting of the Western section of the AUA. In light of the available interventional treatment options, she pointed out that many questioned the need for medical management. However, stone recurrence rates are 65-90%, and there have been no new metabolic agents approved by the FDA since the introduction Read the rest of this entry »

The effectiveness of BANZEL as adjunctive treatment for the seizures associated with Lennox-Gastaut syndrome was established in a single multicenter, double-blind, placebo-controlled, randomized, parallel-group study (n=138). Male and female patients (between 4 and 30 years of age) were included if they had a diagnosis of inadequately controlled seizures associated with LGS (including both atypical absence seizures and drop attacks) and were being Read the rest of this entry »

NovaDel Pharma received FDA clearance to launch Zolpimist, an oral spray that treats insomnia short term, in 5-mg and 10-mg doses. The approval was based on results from two randomized trials comparing Zolpimist with Ambien, a common prescription sleep aid. Both products use the same active ingredient.
Wednesday, April 16, 2008
Tuesday, August 5, 2008
Thursday, May 15, 2008
Monday, December 22, 2008
Monday, December 22, 2008
Friday, November Read the rest of this entry »

AstraZeneca Plc said today that SEROQUEL XR, the
antipsychotic medication that is used to treat schizophrenia, received the Food
and Drug Administration approval.
AstraZeneca, one of the world’s leading pharmaceutical
companies, announced the FDA approved SEROQUEL XR (Quetiapine Fumarate
Extended-Release Tablets) for the acute treatment of bipolar depression and
mania. This is the first FDA-approved drug of this kind.
Bipolar disorder, also Read the rest of this entry »